期刊文献+
共找到175篇文章
< 1 2 9 >
每页显示 20 50 100
Combined gastroscopic and laparoscopic resection of gastric metastatic adenosquamous carcinoma from lung: A case report
1
作者 Yin Lin Yi-Long Wu +2 位作者 Dong-Dong Zou Xiao-Long Luo Shi-Yan Zhang 《World Journal of Gastrointestinal Surgery》 SCIE 2024年第9期3065-3073,共9页
BACKGROUND Primary lung cancer is the leading cause of cancer-related death worldwide.Common metastatic sites include the brain,liver,bones,and adrenal glands.However,gastric metastases from lung cancer are rare.This ... BACKGROUND Primary lung cancer is the leading cause of cancer-related death worldwide.Common metastatic sites include the brain,liver,bones,and adrenal glands.However,gastric metastases from lung cancer are rare.This case may be the first report of a combined gastroscopic and laparoscopic resection for gastric metasta-tic adenosquamous carcinoma(ASC).CASE SUMMARY We report a case of gastric metastasis from lung cancer.The patient was a 61-year-old Han Chinese female who first attended our hospital complaining of a per-sistent cough,leading to the diagnosis of advanced-stage lung adenocarcinoma.After more than four years of chemotherapy,the patient began to experience epi-gastric pain.Endoscopy was performed,and pathological examination of biopsy specimens confirmed that the gastric lesion was a metastasis from lung cancer.The lesion was successfully resected by combined gastroscopy and laparoscopy.Histopathological examination of the resected gastric specimen revealed ASC.CONCLUSION Gastric metastases from lung cancer are rare.Endoscopy,histological and immunohistochemical staining are useful for diagnosing metastatic lesions.Surgical management may provide extended survival in appropriately selected patients. 展开更多
关键词 Primary lung cancer Gastric metastasis Endoscopic submucosal dissection Laparoscopic surgery Adenosquamous carcinoma Case report
下载PDF
Relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma 被引量:5
2
作者 Cheng-De Wang Xin-Rong Wang +2 位作者 Chao-Yang Wang Yi-Jun Tang Ming-Wen Hao 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2015年第3期249-252,共4页
Objective:To study the relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma.Methods:A total of 297 patients from July 2009 to May 2013 were chosen as ... Objective:To study the relevance of EGFR gene mutation with pathological features and prognosis in patients with non-small-cell lung carcinoma.Methods:A total of 297 patients from July 2009 to May 2013 were chosen as objects.EGFR gene mutation were detected with fluorescence quantitative PCR.Relevance of EGFR gene mutation with clinical and pathological features was analyzed,and the prognosis of EGFR- mutant-patients and that of EGFR- wide type-patients was compared.Results:In 297 patients.136(45.79%) showed EGFR gene mutation.EGFR gene mutation had no significant relevance with age.gender,smoking history,family history of cancer and clinical stage(P>0.05);there was significant relevance between EGFR gene mutation and blood type,pathologic types,differentiation and diameter of cancer(P<0.05).The difference between prognosis of EGFR- mutant-patients and that of EGFR- wide type-patients was statistical significance(P<0.05).Conclusions:EGFR gene mutation has significant relevance with pathological features,the prognosis of EGFRmutant-paticnts is better than that of EGFR- wide type-patients. 展开更多
关键词 EPIDERMAL growth factor receptor non-small-cell lung carcinoma Fluorescence quantitative PCR PATHOLOGICAL features PROGNOSIS
下载PDF
Inhibitory Effect of MiR-449b on Cancer Cell Growth and Invasion through LGR4 in Non-Small-Cell Lung Carcinoma 被引量:8
3
作者 Dong YANG Jin-song LI +2 位作者 Qian-yu XU Tian XIA Jia-hong XIA 《Current Medical Science》 SCIE CAS 2018年第4期582-589,共8页
Non-small-cell lung carcinoma (NSCLC) is one of the most frequently diagnosed malignancies worldwide. Previous studies have shown that microRNA-449b (miR-449b) functions as a tumor suppressor in many cancers. Howe... Non-small-cell lung carcinoma (NSCLC) is one of the most frequently diagnosed malignancies worldwide. Previous studies have shown that microRNA-449b (miR-449b) functions as a tumor suppressor in many cancers. However, the role of miR- 449b in NSCLC is still unknown. In the present study, miR-449b was significantly down- regulated in NSCLC samples and cell lines. Bioinformatics analysis revealed that 3'-UTR region of leucine rich repeat containing G protein-coupled receptor 4 (LGR4) mRNA had putative complementary sequences to miR-449b, which was further confirmed by the luciferase assay. Western blotting showed that restoration of miR-449b in NSCLC cells decreased the expression of LGR4. Interestingly, over-expression of miR-449b inhibited growth and invasion of NSCLC cells in vitro. Furthermore, ectopic expression of LGR4 reversed miR-449b-suppressed proliferation and invasion of NSCLC cells. Therefore, the data of the present study demonstrate that miR-449b inhibits tumor cell growth and invasion by targeting LGR4 in NSCLC. 展开更多
关键词 non-small-cell lung carcinoma microRNA-449b leucine rich repeat containing G protein-coupled receptor 4 growth INVASION
下载PDF
Clinical Observation on Treatment of NonParvicellular Carcinoma of the Lung with Jin Fu Kang Oral Liquid 被引量:1
4
作者 刘嘉湘 施志明 +6 位作者 徐振晔 朱晏伟 赵丽红 李和根 高虹 陈善香 刘煜 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2000年第2期96-100,共5页
Jin Fu Kang Oral Liquid ([symbol: see text]), made of traditional Chinese drugs for supplementing qi and nourishing yin, was developed according to the common symptoms in lung carcinoma with deficiency of both qi and ... Jin Fu Kang Oral Liquid ([symbol: see text]), made of traditional Chinese drugs for supplementing qi and nourishing yin, was developed according to the common symptoms in lung carcinoma with deficiency of both qi and yin. Of the 96 cases in the Jin Fu Kang group, 1 case got complete remission (CR) after treatment, 8 cases partial remission (PR), 52 cases no change (NC), PR + NC covering 63.5%. Of the 52 cases in the group of Jin Fu Kang plus chemotherapy, 11 cases got PR after treatment, 26 cases NC, PR + NC covering 71.2%. Of the 25 cases in the chemotherapy group, 4 cases got PR after treatment, 11 cases NC, PR + NC covering 60.0%. The results show that the therapeutic effectiveness in the Jin Fu Kang group and the group of Jin Fu Kang plus chemotherapy was better than that in the chemotherapy group. The one-year survival rate and the two-year survival rate after treatment in the Jin Fu Kang group were 67.3% and 67.3% respectively; 66.7% and 66.7% in the group of Jin Fu Kang plus chemotherapy; and 40.3% and 0.0% in the chemotherapy group. The improvement of clinical symptoms, increase of body weight and improvement of health situation (KPS marks) after treatment in both the Jin Fu Kang group and the group of Jin Fu Kang plus chemotherapy were better than that in the chemotherapy group. Some indicators of immunology and hemogram after treatment were greatly improved in the Jin Fu Kang group, worse in the chemotherapy group, but no obvious improvement in the group of Jin Fu Kang plus chemotherapy. 展开更多
关键词 ADENOcarcinoma carcinoma non-small-cell lung carcinoma Squamous Cell Drugs Chinese Herbal Humans lung Neoplasms
下载PDF
Pembrolizumab-emerging treatment of pulmonary sarcomatoid carcinoma: A case report 被引量:2
5
作者 Emanuela Cimpeanu Jibran Ahmed +4 位作者 Wahib Zafar Adreana DeMarinis Svetoslav S Bardarov Shamim Salman Dennis Bloomfield 《World Journal of Clinical Cases》 SCIE 2020年第1期97-102,共6页
BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previously rapidly fatal subtype of nonsmall-cell lung cancer.CASE SUMMARY We report the case of a 69-... BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previously rapidly fatal subtype of nonsmall-cell lung cancer.CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells.The patient was started on pembrolizumab and,after 5 cycles,there was a more than 80 percent decrease in the size of the tumor mass.Further decrease was seen at the end of 10 cycles.The patient has been tolerating pembrolizumab well,with no limiting side-effects.Fourteen months after first coming into the hospital,he remains asymptomatic.CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC. 展开更多
关键词 Pembrolizumab Pulmonary sarcomatoid carcinoma Programmed deathligand 1 Platinum-based chemotherapy non-small-cell lung cancer Overall survival Case report
下载PDF
Advances in adjuvant systemic therapy for non-small-cell lung cancer 被引量:7
6
作者 David Leong Rajat Rai +2 位作者 Brandon Nguyen Andrew Lee Desmond Yip 《World Journal of Clinical Oncology》 CAS 2014年第4期633-645,共13页
Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Da... Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies. 展开更多
关键词 carcinoma non-small-cell lung CHEMOTHERAPY ADJUVANT RADIOTHERAPY Biological therapy BIOMARKER
下载PDF
Pang Fuwan Uses Yao Medicine to Observe the Therapeutic Effects on the Physical and Mental Symptoms of Patients with Advanced Non-Small Cell Lung Cancer
7
作者 Qiuxiang Luo Qiongping Liang Xiaoyan Luo 《Pharmacology & Pharmacy》 2024年第3期62-69,共8页
Objective: Investigate the efficacy and safety of Yao Medicine in the treatment of advanced non-small-cell lung carcinoma, and explore the best therapeutic measure for clinical benefit. Methods: From July 2020 to July... Objective: Investigate the efficacy and safety of Yao Medicine in the treatment of advanced non-small-cell lung carcinoma, and explore the best therapeutic measure for clinical benefit. Methods: From July 2020 to July 2022, 84 patients with advanced non-small-cell lung carcinoma were selected and randomly divided into the Observation Group and control group, and the control group was treated with routine Western medicine, with 42 cases in each group. The activity of daily living (ADL) was assessed before and after treatment, meanwhile, the self-rating depression scale (SDS) and self-rating anxiety SAS (SAS) were used to assess the improvement of a bad mood, and quality of life SF-36 was used to assess the quality of life, to judge the efficacy and safety. Results: The effective rate of observation group was 91.67%. The effective rate of the control group was 76.19%. The effective rate of the observation group was significantly higher than that of the control group (P 0.05). There were no significant differences in the scores of SDS, SAS and quality of life between the two groups before treatment (P > 0.05), and after treatment, the scores of SDS, SAS and quality of life in the two groups were compared with those in the control group (P > 0.05), the scores of VAS, SDS and SAS decreased significantly, while ESCV, angle of straight leg elevation, ADL, physiological score, emotional score, social score and health status score increased significantly, the difference was statistically significant (P 0.05). Conclusion: Yao Medicine can improve the psychosomatic symptoms of patients with advanced non-small-cell lung carcinoma better, with better efficacy and higher safety. 展开更多
关键词 Yao Medicine non-small-cell lung carcinoma Advanced Stage EFFICACY Physical and Mental
下载PDF
Unresectable stage Ⅲ non-small-cell lung cancer: Have we made any progress?
8
作者 Carolien De Tollenaere Yolande Lievens +2 位作者 Katrien Vandecasteele Karim Vermaelen Veerle Surmont 《World Journal of Respirology》 2015年第2期140-151,共12页
Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanced... Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanceddisease in patients with good performance status consists of combined modality therapy in particular concurrent chemoradiotherapy. But despite a lot of efforts done in the past, local control and survival of patients with unresectable stage Ⅲ non-small-cell lung cancer(NSCLC) remains poor. Improving outcomes for patients with unresectable stage Ⅲ NSCLC has therefore been an area of ongoing research. Research has focused on improving systemic therapy, improving radiation therapy or adding a maintenance therapy to consolidate the initial therapy. Also implementation of newer targeted therapies and immunotherapy has been investigated as well as the option of prophylactic cranial irradiation. This article reviews the latest literature on improving local control and preventing distant metastases. It seems that we have reached a plateau with conventional chemotherapy. Radiotherapy dose escalation did not improve outcome although increasing radiation dose-intensity with new radiotherapy techniques and the use of newer agents, e.g., immunotherapy might be promising. In the future well-designed clinical trials are necessary to prove those promising results. 展开更多
关键词 StageⅢnon-small-cell lung carcinoma CHEMORADIOTHERAPY Induction CHEMOTHERAPY Molecular targeted therapy Consolidation CHEMOTHERAPY Doseescalation Altered fractionation Advanced radiotherapy techniques PROPHYLACTIC CRANIAL irradiation
下载PDF
Therapy for non-small-cell lung cancer patients with brain metastasis 被引量:1
9
作者 Bing Li Yuchen Bao +1 位作者 Bin Chen Songwen Zhou 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第10期483-488,共6页
Brain metastasis is a major cause of poor prognosis and high mortality for non-small cell lung cancer patients. The prognosis of non-small-cell lung cancer(NSCLC) patients with brain metastasis is generally poor and m... Brain metastasis is a major cause of poor prognosis and high mortality for non-small cell lung cancer patients. The prognosis of non-small-cell lung cancer(NSCLC) patients with brain metastasis is generally poor and more effective treatment is required to improve their prognosis. Whole-brain radiotherapy, surgery, stereotactic radiosurgery, chemotherapy and targeted therapy are the main treatment for brain metastasis. This review focuses on the five therapeutic strategy and in particular, on targeted therapy. 展开更多
关键词 non-small-cell lung cancer(NSCLC) brain metastasis whole-brain radiotherapy surgery stereotactic radiotherapy CHEMOTHERAPY targeted therapy
下载PDF
In Surgical Treatment of Non-Small-Cell Lung Cancer a Minimum Number of Resected Mediastinal Lymph Nodes Is Mandatory for Accurate Staging
10
作者 Armin Kolb Elena Steidele +3 位作者 Craig Matthews Johannes Merk Karl-Heinz Orend Bernd Mühling 《Surgical Science》 2014年第10期471-478,共8页
Objective: Increased numbers of removed lymph nodes (LN) are resulting in more accurate staging of the patient (Will-Rogers-Phenomenon). This study evaluates dependence of lymph node sample size to 1) Will-Rogers-Phen... Objective: Increased numbers of removed lymph nodes (LN) are resulting in more accurate staging of the patient (Will-Rogers-Phenomenon). This study evaluates dependence of lymph node sample size to 1) Will-Rogers-Phenomenom, 2) influence of sample size on overall survival and in?terms of 3) morbidity and mortality. Methods: 131 patients after pulmonary resection were?retrospectively analysed concerning surgery, number of removed lymph nodes, stage, complications and survival. Patients were stratified according to the median number of lymph nodes in two groups (A <12 lymph nodes and B ≥12 lymph nodes). Results: 5% of the patients had only local lymphadenectomy and in 14% a systematic lymphadenectomy was performed. 17% of the patients showed skip metastasis. Lymph node positivity was correlated to the number of removed lymph nodes (p = 0.003). The approximated median survival for UICC (Union internationale contre le cancer) stage I was 511, stage II 521 and stage III 290 days. Subgroup analysis of survival data showed in group A an approximated median survival at stage I of 495 days, at II 537 days and at III 451.5 days. Group B showed at stage I 675 days, at II 521 days and at III 221 days. There was no difference in complications and mortality. Conclusion: A too low sample size leads to understaging due to skip metastasis. Obligatory mediastinal lymph node sampling would decrease the risk of understaging due to skip metastasis and does not increase morbidity or complications. Lymph node sampling is not inferior concerning morbidity and survival in our patient collective. This study cannot recommend a minimum number of LN to be resected. The evaluated limit of 12 LN proves to be suitable as a guideline. 展开更多
关键词 lung CANCER surgery LYMPH NODE LYMPHADENECTOMY LYMPH NODE Sampling Systematic LYMPHADENECTOMY Nsclc non-small-cell lung CANCER
下载PDF
Apoptosis of Lewis Lung Carcinoma Cells Induced by Microwave via p53 and Proapoptotic Proteins In vivo 被引量:1
11
作者 Kou-Dong Zhang Lin-Rong Tong +6 位作者 Shui-Ming Wang Rui-Yun Peng Hai-Dong Huang Yu-Chao Dong Xing-Xing Zhang Qiang Li Chong Bai 《Chinese Medical Journal》 SCIE CAS CSCD 2017年第1期15-22,共8页
Background: Microwave therapy is a minimal invasive procedure and has been employed in clinical practice for the treatment of various types of cancers. However, its therapeutic application in non-small-cell lung canc... Background: Microwave therapy is a minimal invasive procedure and has been employed in clinical practice for the treatment of various types of cancers. However, its therapeutic application in non-small-cell lung cancer and the underlying mechanism remains to be investigated. This study aimed to investigate its effect on Lewis lung carcinoma (LLC) tumor in vivo. Methods: Fifty LLC tumor-bearing C57BL/6 mice were adopted to assess the effect of microwave radiation on the growth and apoptosis of LLC tumor in vivo. These mice were randomly assigned to 10 groups with 5 mice in each group. Five groups were treated by single pulse microwave at different doses for different time, and the other five groups were radiated by multiple-pulse treatment of a single dose. Apoptosis of cancer cells was determined by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay. Western blotting was applied to detect the expression of proteins. Results: Single pulse of microwave radiation for 5 min had little effect on the mice. Only 15-min microwave radiation at 30 mW/cm2 significantly increased the mice body temperature (2.20 ± 0.82)℃ as compared with the other groups (0.78 ± 0.29 ℃, 1.24 ± 0.52 ℃, 0.78 ± 0.42 ℃, respectively), but it did not affect the apoptosis of LLC tumor cells significantly. Continous microwave radiation exposure, single dose microwave radiation once per day for up to seven days, inhibited cell division and induced apoptosis of LLC tumor cells in a dose- and duration-dependent manner. It upregulated the protein levels of p53, Caspase 3, Bax and downregulated Bcl-2 protein. Conclusions: Multiple exposures of LLC-bearing mice to microwave radiation effectively induced tumor cell apoptosis at least partly by upregulating proapoptotic proteins and downregulating antiapoptotic proteins. Continuous radiation at low microwave intensity Ibr a short time per day is promising in treating non-small-cell lung cancer. 展开更多
关键词 APOPTOSIS Lewis lung carcinoma Cells Microwave Radiation non-small-cell lung Cancer
原文传递
Lung squamous cell carcinoma combined with tuberculous pleurisy
12
作者 ZHANG Yi YAO Shu-yang +1 位作者 LI Yuan-bo ZHANG Jian 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第20期3755-3756,共2页
A58-year old male patient was admitted to our .hospital with repeated coughing, expectoration withblood in the sputum for more than 10 months, bilateral wrists and ankles with pain and afternoon low fever, chest tight... A58-year old male patient was admitted to our .hospital with repeated coughing, expectoration withblood in the sputum for more than 10 months, bilateral wrists and ankles with pain and afternoon low fever, chest tightness and shortness of breath in the latest one month. The patient had a history of joint pain for more than 3 years without special treatment. He had a smoking history for more than 30 years with 10 cigarettes a day. He had no family tumor history. Physical examination: T 38.5℃, P 100/min, R 22/min, blood pressure (BP) 107/77 mmHg; the double upper fingers visible clubbing, bilateral supraclavicular lymph node not feelable, left inferior pulmonary respiratory sounds disappeared, and wet and dry sounds not heard. 展开更多
关键词 lung squamous cell carcinoma DIAGNOSIS tuberculous pleurisy surgery
原文传递
ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL SURGERYFOR NON-SMALL CELL LUNG CANCER:A RANDOMIZED STUDY
13
作者 徐光川 戎铁华 林鹏 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1999年第1期74-77,共4页
Objective: To evaluate the efficacy of adjuvant chemotherapy after radical surgery for non-small cell lung cancer (NSCLC). Methods: Seventy patients with NSCLC (stage I–III) undergone radical surgery were randomized ... Objective: To evaluate the efficacy of adjuvant chemotherapy after radical surgery for non-small cell lung cancer (NSCLC). Methods: Seventy patients with NSCLC (stage I–III) undergone radical surgery were randomized into two groups: 35 patients received adjuvant chemotherapy with cyclophosphamide (CTX) 300 mg/m2, vincristine (VCR) 1.4% mg/m2, adriamycin (ADM) 50 mg/m2, lomustine (CCNU) 50 mg/m2 dl, cisplatin (DDP) 20 mg/m2, d1–5, for 4 cycles, and followed by oral Ftorafur (FT-207) 600–900 mg/d for 1 year (adjuvant chemotherapy group). The other 35 patients received surgical treatment only (surgery group). Results: The overall 5-year survival rate was 48.6% in the adjuvant chemotherapy group, and 31.4% in the surgery group, respectively. The difference between the two groups was not statistically significant (P>0.05). The 5-year survival rate of patients in stage III was 44.0% and 20.8% received surgery with and without adjuvant chemotherapy, respectively. The difference between the two groups was statistically significant (P<0.025). The 5-year survival rate of patients in stage I–II in the two groups was 60.0% and 54.5%, respectively (P>0.75). Conclusion: Postoperative adjuvant chemotherapy in NSCLC can improve survival, for those patients in stage III, it suggests significantly 5-year survival rate in the adjuvant chemotherapy group was higher than that in the surgery alone group. 展开更多
关键词 Non small cell lung carcinoma Radical surgery Adjuvant chemotherapy Survival rate
下载PDF
Partial removal of the pulmonary artery in video-assisted thoracic surgery for non-small cell lung cancer 被引量:2
14
作者 Keping Xu Zhi Zhang +3 位作者 Jianqiang Zhao Jianfeng Huang Rong Yin Lin Xu 《The Journal of Biomedical Research》 CAS 2013年第4期310-317,共8页
Lobectomy with partial removal of the pulmonary artery in video-assisted thoracic surgery (VATS) currently remains a challenge for thoracic surgeons. We were interested in introducing pulmonary vessel blocking techn... Lobectomy with partial removal of the pulmonary artery in video-assisted thoracic surgery (VATS) currently remains a challenge for thoracic surgeons. We were interested in introducing pulmonary vessel blocking techniques in open thoracic surgery into video-assisted thoracic surgery (VATS) procedures. In this study, we reported a surgical technique simultaneously blocking the pulmonary artery and the pulmonary vein for partial removal of the pulmonary artery under VATS. Seven patients with non-small-cell lung cancer (NSCLC) received lobectomy with partial removal of the pulmonary artery using the technique between December 2007 and March 2012. Briefly, rather than using a small clamp on the distal pulmonary artery to the area of invading cancer, we replaced a vascular clamp with a ribbon and Hem-o-lock clip to block the preserved pulmonary veins so as to prevent back bleeding and yield a better view for surgeons. The mean occlusion time of the pulmonary artery and pulmonary veins were 44.0±10.0 and 41.3±9.7 minutes, respectively. The mean repair time of the pulmonary artery was 25.3±13.7 minutes. No complications occurred. No patients showed abnormal blood flow through the reconstructed vessel. There were no local recurrences on the pulmonary artery. In conclusion, the technique for blocking the pulmonary artery and veins is feasible and safe in VATS and reduces the risk of abrupt intraoperative bleeding and the chance of converting to open thoracotomy, and extends the indications of VATS lobectomy. 展开更多
关键词 video-assisted thoracic surgery (VATS) non-small-cell lung cancer (NSCLC) LOBECTOMY pulmonary artery reconstruction
下载PDF
The Therapeutic Effects of the Radiotherapy Plus TCM Treatment Observed in Senile Non-Parvicellular Lung Cancer Patients at the Late Stage
15
作者 蓝孝筑 姜玉华 王薇 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2003年第1期32-34,共3页
47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases)... 47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.The patients in the treatment group orally took Chinese medicine during and after the radiotherapy.There was no obvious difference in short-term therapeutic effects between the two groups,but the long-term curative effects in the treatment group was obviously superior to that in the control group (P<0.05 or P<0.01).Conclusion:radiotherapy plus TCM can prolong the survival period for senile non-parvicellular lung cancer patients. 展开更多
关键词 PHYTOTHERAPY Aged carcinoma non-small-cell lung carcinoma Squamous Cell Combined Modality Therapy Drugs Chinese Herbal Female Follow-Up Studies Humans lung Neoplasms Male
下载PDF
Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer 被引量:6
16
作者 Fariz Nurwidya Akiko Murakami +1 位作者 Fumiyuki Takahashi Kazuhisa Takahashi 《Clinical oncology and cancer researeh》 CAS CSCD 2012年第1期18-22,共5页
One of the most important pathways in non-small cell lung cancer(NSCLC) is the epidermal growth factor receptor(EGFR) pathway. This pathway affects several crucial processes in tumor development and progression,includ... One of the most important pathways in non-small cell lung cancer(NSCLC) is the epidermal growth factor receptor(EGFR) pathway. This pathway affects several crucial processes in tumor development and progression,including tumor cell proliferation,apoptosis regulation,angiogenesis,and metastatic invasion.Targeting EGFR is currently being intensely explored.We are witnessing the development of a number of potential molecular-inhibiting treatments for application in clinical oncology.In the last decade,the tyrosine kinase(TK) domain of the EGFR was identified in NSCLC patients,and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib.Unfortunately,there were primary and/or secondary resistance to these treatments,as shown by clinical trials.Subsequent molecular biology studies provided some explanations for the drug resistance phenomenon.The molecular mechanisms of resistance need to be clarified.An in-depth understanding of these targeted-therapy resistance may help us explore new strategies for overcoming or reversing the resistance to these inhibitors for the future of NSCLC treatment. 展开更多
关键词 carcinoma non-small-cell lung MUTATION drug resistance
下载PDF
A Prospective Randomized Study of Adjuvant Chemotherapy in Completely Resected Stage III-N2 Non Small Cell Lung Cancer 被引量:1
17
作者 王思愚 区伟 +4 位作者 林勇斌 梁颖 叶雄 张彬彬 杨桦 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2007年第3期189-194,共6页
To evaluate the effect of postoperative adjuvant chemotherapy on survival after complete resection of stage III-N2 non-small-cell lung cancer. Methods: From Jan. 1999 to Dec. 2003, one-hundred and fifty patients, who... To evaluate the effect of postoperative adjuvant chemotherapy on survival after complete resection of stage III-N2 non-small-cell lung cancer. Methods: From Jan. 1999 to Dec. 2003, one-hundred and fifty patients, who were diagnosed as stage III-N2 non-small cell lung cancer after operation, were randomly devided into chemotherapy group and control group. The former received four cycles of chemotherapy with NVB (25 mg/m^2, D1, D5)/paclitaxel (175 mg/m^2, D1) and Carboplatin (AUC=5, D1). Results: In chemotherapy group, 75.8% (68/79) of patients had finished the 4 cycles of chemotherapy and no one died of toxic effects of chemotherapy. Twenty-five percent of the patients had grade 3-4 neutropenia and 2% had febrile neutropenia. The median survival for the entire 150 patients was 879 d, with 1-year survival rate of 81%, 2-year survival rate of 59% and 3-year survival rate of 43%. There was no significant difference in median survival between chemotherapy and control group (897 d vs 821 d, P=0.0527), but there was significant difference in the 1-year and 2-year overall survival (94.71%, 76.28% vs 512 d, P=0.122), but there was significant difference in the 2-year survival rate between two groups with brain metastases (66.7% vs 37.6% P〈0.05). The median survival after brain metastasis appeared was 190 days. Conclusion: Postoperative adjuvant chemotherapy does not significantly improve median survival among patients with completely resected stage II-N2 non-small-cell lung cancer, but significantly improves the 1-year and 2-year overall survival. It neither decreases the incidence of brain metastasis but put off the time of brain metastasis. 展开更多
关键词 lung cancer carcinoma Non-small lung cancer Adjuvant chemotherapy surgery
下载PDF
Value of COX-2 and HER-2 in Judging Condition and Prognosis in Non-Small Cell Lung Cancer Patients 被引量:2
18
作者 Lei YANG Jun-guo LU Qing-he TAN Jin-zhi WEI Xiao-dong ZHANG Hong-bing GU 《Clinical oncology and cancer researeh》 CAS CSCD 2010年第3期200-205,共6页
OBJECTIVE To investigate the expressions of cyclooxygenase 2 (COX-2) and human epidermal growth factor receptor-2 (HER-2) in non-small cell lung cancer (NSCLC) and their clinical significance in identifying the ... OBJECTIVE To investigate the expressions of cyclooxygenase 2 (COX-2) and human epidermal growth factor receptor-2 (HER-2) in non-small cell lung cancer (NSCLC) and their clinical significance in identifying the progression and prognosis of the NSCLC patients. METHODS Immunohistochemical indirect method was used to detect the expressions of the COX-2 and HER-2 protein in 54 NSCLC specimens, 16 paraneoplastic specimens, and 10 normal tissue specimens. RESULTS The positive rates of COX-2 and HER-2 protein expressions were respectively 75.9% and 40.7% in the NSCLC specimens, 25% and 12.5% in the paraneoplastic specimens, and 0 in the normal tissue. The COX-2 protein expression in lung cancer (LC) was not only related to the smoking habit of the patients and histological grades of LC, but also to the TNM stages, and lymphatic metastasis (P 〈 0.05). HER-2 protein expression closely correlated to the pathologic types, histological grades, TNM stages, and lymphatic metastasis (P 〈 0.05). The result of univariate analysis showed that all the histological grades, TNM stages, lymphatic metastasis, and expressions of COX-2/HER-2 correlated to the prognosis of NSCLC patients (mean of P value 〈 0.01). The multivariate survival analysis indicated that there were signi.cant di.erences in comparison of the survival time between the COX-2 (++/+++) /HER-2 (++/+++) and the COX-2 (-/+)/HER-2 (-/+) groups (P〈 0.001), suggesting the COX-2/HER-2 was a negative prognostic factor. CONCLUSION COX-2 and HER-2 are valuable in identifying the progression of NSCLC and predicting the prognosis of NSCLC patients. COX-2 and HER-2 are useful for judging the NSCLC patient's condition, and are of great value to the decision of NSCLC prognosis. 展开更多
关键词 carcinoma non-small-cell lung cyclooxygenase 2 ERBB2 protein human IMMUNOHISTOCHEMISTRY PROGNOSIS
下载PDF
Role of positron emission tomography-computed tomography in non-small cell lung cancer 被引量:2
19
作者 Pankaj Kumar Garg Saurabh Kumar Singh +2 位作者 Gaurav Prakash Ashish Jakhetiya Durgatosh Pandey 《World Journal of Methodology》 2016年第1期105-111,共7页
Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell carcinoma and small cell carcinoma are the main histological subtypes and constitutes around 85% and 15% of all lung cancer respec... Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell carcinoma and small cell carcinoma are the main histological subtypes and constitutes around 85% and 15% of all lung cancer respectively. Multimodality treatment plays a key role in the successful management of lung cancer depending upon the histological subtype, stage of disease, and performance status. Imaging modalities play an important role in the diagnosis and accurate staging of the disease, in assessing the response to neoadjuvant therapy, and in the follow-up of the patients. Last decade has witnessed voluminous upsurge in the use of positron emission tomography-computed tomography(PET-CT); role of PET-CT has widened exponentially in the management of lung cancer. The present article reviews the role of 18-fluoro-deoxyglucose PET-CT in the management of non small cell lung cancer with emphasis on staging of the disease and the assessment of response to neoadjuvant therapy based on available literature. 展开更多
关键词 POSITRON emission tomography Diagnostic imaging NEOPLASM STAGING carcinoma non-small-cell lung cancer lung NEOPLASMS
下载PDF
老年非小细胞癌病人术后“教科书式结局”的影响因素及预后价值分析
20
作者 底盼盼 李歆 +2 位作者 刘丽洁 张琳 魏学燕 《安徽医药》 CAS 2024年第5期971-976,共6页
目的分析老年非小细胞肺癌(NSCLC)病人行根治性手术后达成“教科书式结局”(TO)的影响因素,并探讨TO对病人预后的影响。方法收集2012年1月至2017年12月石家庄市妇幼保健院接受手术的555例临床分期为Ⅰ~Ⅱ期的老年NSCLC病人的临床资料,... 目的分析老年非小细胞肺癌(NSCLC)病人行根治性手术后达成“教科书式结局”(TO)的影响因素,并探讨TO对病人预后的影响。方法收集2012年1月至2017年12月石家庄市妇幼保健院接受手术的555例临床分期为Ⅰ~Ⅱ期的老年NSCLC病人的临床资料,根据是否达成TO分为TO组与非TO组。应用logistic回归模型分析影响TO达成的独立危险因素,并构建列线图预测模型。模型的预测效能与一致性通过受试者操作特征(ROC)曲线与一致性曲线评估。应用Kaplan-Meier生存曲线与Cox回归模型评价TO的预后价值。结果555例NSCLC病人中,372例(67.0%)成功达成TO。与未达成TO的病人相比,达成TO者的年龄较小、多为女性、吸烟者较少、共病指数较小、术前第1秒用力呼气量占预计值百分比(FEV1%)与一氧化碳弥散量占预计值百分比(DLCO%)较高、多接受胸腔镜手术并且肿瘤多为腺癌(P<0.05)。多因素分析结果表明,性别、共病指数、术前DLCO%与手术方式是TO达成的独立影响因素(P<0.05)。结合以上4个因素构建的列线图预测模型具有一定的预测效能(AUC=0.74)与较好的一致性(Hosmer-Lemeshow P=0.287)。生存分析显示,达成TO的病人其术后生存显著优于未达成TO的病人(P<0.05),并且TO是术后生存的独立影响因素(P<0.05)。结论年龄、性别、DLCO%与手术方式是影响老年NSCLC病人在接受肺癌根治术后达成TO的独立预测因素,同时达成TO的病人具有显著更好的预后。 展开更多
关键词 非小细胞肺 手术 教科书式结局 预测模型 生存
下载PDF
上一页 1 2 9 下一页 到第
使用帮助 返回顶部